Related Experiment Video
Updated: Apr 17, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Recent Advances in Understanding the Biology of Castration-Resistant Prostate Cancer
David Lluís1, Wanli Cheng2, Josep Maria Piulats3
1Medical Oncology Department, Catalan Institute of Cancer (ICO), L'Hospitalet de Llobregat, Barcelona 08907, Spain; Department for BioMedical Research, Urology Research Laboratory, University of Bern, Bern 3008, Switzerland.
Abstract:
Prostate cancer progression is largely driven by androgen receptor signaling. While androgen deprivation therapy remains a cornerstone of treatment, it imposes a selective pressure that ultimately leads to the emergence of a castration-resistant phenotype, driven by a range of adaptive molecular mechanisms. In recent years, significant advances have been made in understanding its complex biology, making it a critical focus of ongoing research. The application of multi-omics approaches has played a pivotal role in uncovering the molecular underpinnings of this disease, offering deeper insights into its heterogeneity and resistance mechanisms.
Insights
Prostate cancer growth relies on androgen receptor signaling. Castration-resistant prostate cancer emerges due to treatment resistance, with multi-omics revealing its complex biology and adaptive mechanisms.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Prostate cancer progression is primarily driven by androgen receptor (AR) signaling.
- Androgen deprivation therapy (ADT) is a standard treatment but often leads to castration-resistant prostate cancer (CRPC).
- CRPC develops through adaptive molecular mechanisms, highlighting the need for deeper biological understanding.
Purpose of the Study:
- To investigate the molecular mechanisms underlying prostate cancer progression and resistance to therapy.
- To explore the role of multi-omics approaches in deciphering CRPC biology.
- To gain insights into the heterogeneity and adaptive strategies of castration-resistant prostate cancer.
Main Methods:
- Utilized multi-omics approaches (genomics, transcriptomics, proteomics, etc.) to analyze CRPC samples.
- Integrated multi-omics data to identify key molecular pathways and alterations.
- Correlated molecular findings with clinical data to understand resistance mechanisms.
Main Results:
- Identified specific molecular alterations and signaling pathways driving AR-dependent and AR-independent CRPC.
- Uncovered significant heterogeneity in molecular profiles across CRPC tumors.
- Demonstrated the utility of multi-omics in revealing adaptive mechanisms conferring treatment resistance.
Conclusions:
- Androgen receptor signaling remains central to prostate cancer, but adaptive mechanisms drive resistance to ADT.
- Multi-omics approaches are essential for understanding the complex biology and heterogeneity of CRPC.
- Further research into these molecular underpinnings is critical for developing novel therapeutic strategies for advanced prostate cancer.
